MINDMAZE THERAPEUTICS HOLDING SA

MindMaze Therapeutics announced the launch of MindMotion Lite by the end of 2026, a tablet-based solution that brings the full range of MindMotion neurotherapeutic activities into the home. The new product delivers all neurotherapeutic activities available on MindMotion GO through a tablet, significantly reducing the hardware requirements for home deployment while retaining full-body rehabilitation capabilities and supporting teleconsultation and remote management. CEO Zach Henderson said the AHA/ASA guidelines updated in August 2026 emphasize sufficient rehabilitation intensity and continuity of care after stroke, yet access to continued neurotherapy after patients return home remains a critical gap, and MindMotion Lite is designed to help close it. The company said the tablet-based format is designed to enhance patient experience, streamline distribution, and reduce home deployment costs compared with MindMotion GO, supporting a more scalable and capital-efficient expansion of its home-based offering. MindMaze Therapeutics will preview MindMotion Lite at upcoming clinical, healthcare and investor conferences, with further details on commercial availability and launch markets to be shared closer to launch.